Previous 10 | Next 10 |
ALACHUA, Fla. and TAMPA, Fla., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced today that nerve repair patient Christopher (Chris) Brown has bee...
ALACHUA, Fla. and TAMPA, Fla., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and president, will present at the Canacc...
Image source: The Motley Fool. AxoGen, inc (NASDAQ: AXGN) Q3 2021 Earnings Call Nov 3, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: AxoGen, inc (AXGN) Q3 2021 Earnings Call Transcript
AxoGen, Inc. (AXGN) Q3 2021 Earnings Conference Call November 3, 2021 4:30 PM ET Company Participants Peter Mariani – Executive Vice President and Chief Financial Officer Karen Zaderej – Chairman, President and Chief Executive Officer Conference Call Participants Erin Soldatis &...
AxoGen (NASDAQ:AXGN): Q3 Non-GAAP EPS of -$0.09 beats by $0.05; GAAP EPS of -$0.17 beats by $0.03. Revenue of $31.2M (-6.6% Y/Y) misses by $3.03M. Press Release For further details see: AxoGen EPS beats by $0.05, misses on revenue
ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter ended Septemb...
ALACHUA, Fla. and TAMPA, Fla., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report third quarter 2021 financial results on...
ALACHUA, Fla. and TAMPA, Fla., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, announced that it will participate in the 76 th Annual Meeting of th...
ALACHUA, Fla. and TAMPA, Fla., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that the RECON Clinical Study supporting its Biologics L...
Axogen continues posting double-digit growth in volumes against 2019 levels despite trauma, breast recon, and oral-maxillofacial procedures still well below pre-pandemic levels. COVID-19 infections are definitely a short-term risk and an impediment to sales and training efforts, but u...
News, Short Squeeze, Breakout and More Instantly...
ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, b...
2024-07-01 07:30:05 ET Raymond James analyst issues OUTPERFORM recommendation for AXGN on July 1, 2024 05:51AM ET. AXGN was trading at $7.24 at issue of the analyst recommendation. Historical Analyst Recommendations Latest 10 recommendations
ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635(c)(4) in conn...